| Clinical data | |
|---|---|
| Other names | 4-Methylallyloxy-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-methylallyloxyamphetamine; α-Methylmethallylescaline; α-Methyl-MAL; 3C-Methallylescaline |
| Routes of administration | Unknown[1] |
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H23NO3 |
| Molar mass | 265.353 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 159 to 160 °C (318 to 320 °F) |
| |
| |
3C-MAL, also known as4-methylallyloxy-3,5-dimethoxyamphetamine or asα-methylmethallylescaline (3C-methallylescaline), is achemical compound of thephenethylamine,amphetamine, and3C families related to thepsychedelic drug3,4,5-trimethoxyamphetamine (TMA).[1][2] It is the amphetamine (3C)analogue of the psychedelicmethallylescaline (MAL).[1][2] The compound does not appear to have been tested in humans, and its dose,duration, and effects are unknown.[1] Itschemical synthesis has been described.[2] 3C-MAL was first described in thescientific literature byDaniel Trachsel in 2002.[1][2]
Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it. |